ANI Pharmaceuticals market cap is $577.4 m, and annual revenue was $208.48 m in FY 2020

ANI Pharmaceuticals Gross profit (Q1, 2021)34.5 M

ANI Pharmaceuticals Gross profit margin (Q1, 2021), %63.3%

ANI Pharmaceuticals Net income (Q1, 2021)86 K

ANI Pharmaceuticals EBIT (Q1, 2021)3 M

ANI Pharmaceuticals Cash, 31-Mar-202125.1 M

ANI Pharmaceuticals EV735.8 M

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 435.2k | 2.3m | 30.1m | 56.0m | 76.3m | 128.6m | 176.8m | 201.6m | 206.5m | 208.5m |

| 86% | 36% | 69% | |||||||

## Cost of goods sold | 10.0m | 11.5m | 12.7m | 48.8m | 79.0m | 73.0m | 63.2m | 87.2m | ||

## Gross profit | 20.1m | 44.5m | 63.6m | 79.8m | 97.8m | 128.6m | 143.4m | 121.3m | ||

| 67% | 80% | 83% | 62% | 55% | 64% | 69% | 58% | ||

## R&D expense | 44.2m | 16.9m | 1.7m | 2.7m | 2.9m | 2.9m | 9.1m | 15.4m | 19.8m | 16.0m |

## General and administrative expense | 7.0m | 8.2m | 16.4m | 17.9m | 21.2m | 27.8m | 31.6m | 44.1m | 55.8m | 65.0m |

## Operating expense total | 51.2m | 25.1m | 19.2m | 24.5m | 30.9m | 59.8m | 69.5m | 93.2m | 127.0m | 137.3m |

## Depreciation and amortization | 1.1m | 3.9m | 6.9m | 22.3m | 27.9m | 33.7m | 44.6m | 44.6m | ||

## EBIT | 898.0k | 20.0m | 32.7m | 20.1m | 28.3m | 35.4m | 16.4m | (16.0m) | ||

| 3% | 36% | 43% | 16% | 16% | 18% | 8% | (8%) | ||

## Interest expense | 681.6k | 348.0k | 787.0k | 11.0m | 11.3m | 12.0m | 14.8m | 13.0m | 9.5m | |

## Interest income | 15.0k | 8.5k | ||||||||

## Pre tax profit | (27.8m) | 126.0k | 19.4m | 21.7m | 8.7m | 16.3m | 20.1m | 3.2m | (26.0m) | |

## Income tax expense | (121.8k) | 20.0k | (9.4m) | 6.4m | 4.7m | 17.4m | 4.6m | (2.9m) | (3.4m) | |

## Net Income | (51.6m) | (27.7m) | 301.0k | 28.7m | 15.4m | 3.9m | (1.1m) | 15.5m | 6.1m | (22.5m) |

- Source: SEC Filings

- Source: SEC Filings

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (51.6m) | (27.7m) | 301.0k | 28.7m | 15.4m | 3.9m | (1.1m) | 15.5m | 6.1m | (22.5m) |

## Depreciation and Amortization | 148.2k | 258.9k | 1.1m | 3.9m | 6.9m | 22.3m | 27.9m | 33.7m | 44.6m | 44.6m |

## Accounts Receivable | (7.1m) | (4.8m) | (4.6m) | (24.0m) | (12.9m) | (4.7m) | (7.3m) | (23.7m) | ||

## Inventories | (708.0k) | (3.5m) | (5.9m) | (1.9m) | 5.4m | (379.0k) | (7.7m) | (2.8m) | ||

## Accounts Payable | 134.1k | (4.4m) | (565.0k) | 225.0k | (1.0m) | 1.1m | 3.0k | 3.5m | 5.0m | (2.3m) |

## Cash From Operating Activities | (47.9m) | (25.3m) | (5.5m) | 22.0m | 17.3m | 27.5m | 39.4m | 67.1m | 45.6m | 15.3m |

## Purchases of PP&E | (719.9k) | (611.2k) | (191.0k) | (1.1m) | (2.2m) | (4.6m) | (10.4m) | (5.7m) | (6.6m) | (6.1m) |

## Cash From Investing Activities | (719.9k) | (619.1k) | 20.3m | (35.8m) | (32.7m) | (154.1m) | (108.0m) | (27.4m) | (27.5m) | (68.3m) |

## Short-term Borrowings | (7.5m) | |||||||||

## Cash From Financing Activities | 67.7m | 3.5m | (3.7m) | 171.7m | 1.1m | (729.0k) | 72.4m | (27.8m) | 1.3m | (1.4m) |

## Net Change in Cash | 19.1m | (22.4m) | 11.1m | 157.9m | (14.4m) | (127.3m) | 3.8m | 11.9m | 19.3m | (54.5m) |

## Interest Paid | 688.0k | 313.4k | 250.0k | 4.2m | 4.1m | 3.8m | 6.3m | 6.1m | 6.9m | |

## Income Taxes Paid | 147.0k | 13.3m | 9.5m | 17.8m | 6.4m | 10.0m | 5.0m |

- Source: SEC Filings

- Source: SEC Filings

USD | Q2, 2011 |
---|---|

## Financial Leverage | 3.7 x |